There is a select group of publicly traded companies which are pure plays in diabetes. Three of the most notable are Tandem (NASDAQ: TNDM) and Insulet (NASDAQ: PODD) in the insulin pump market and Dexcom (NASDAQ: DXCM) in CGM. Before we go further yes, it is true that the OmniPod does deliver other drugs but this segment of the business continues to be a work in progress.
Looked at on a year to date basis all three of these companies have done very well;
Insulet is up over 36%
Dexcom over 50%
Tandem over 460 . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.